FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2764178891> ?p ?o ?g. }

• W2764178891 endingPage "1084" @default.
• W2764178891 startingPage "1077" @default.
• W2764178891 abstract "Anti-tumour necrosis factor (TNF) agents have improved the care of Crohn's disease (CD). After the first anti-TNF discontinuation, it is possible to switch to another anti-TNF. Three anti-TNF agents are available for ulcerative colitis (infliximab, adalimumab and golimumab), but only the first 2 have been approved for CD because golimumab has not been studied for this indication.To report the efficacy and safety of golimumab in CD.Crohn's disease patients who received golimumab were identified in 12 French tertiary centres and were retrospectively analysed. The primary endpoint was the duration of golimumab treatment before escalation or discontinuation. The clinical response was defined as a decrease of more than 3 points in the Harvey-Bradshaw index or by global physician assessment.One hundred and fifteen patients were included. The golimumab treatment duration was 9.8 months (0.55-44), and 48.7% of the patients were still under treatment at the end of follow-up. Clinical response was observed in 55.8% of the patients after a mean duration of 3.8 months. The probability of remaining under treatment without escalation at 6, 12 and 24 months was 54.6%, 34.9% and 19.3% respectively. In multivariate analysis, discontinuation of the first anti-TNF agent due to intolerance (odds ratio, OR = 2.16; 95% CI, confidence interval [1.25-3.86]; P = .005) and co-immunosuppression for more than 6 months (OR = 3.98; 95% CI [2.3-7.1]; P < .0001) were predictive factors of efficacy. Six per cent of the patients discontinued treatment due to intolerance.After failure of infliximab or adalimumab for Crohn's disease, golimumab was safe and seemed beneficial in half of the patients." @default.
• W2764178891 created "2017-10-20" @default.
• W2764178891 creator A5003276206 @default.
• W2764178891 creator A5005106461 @default.
• W2764178891 creator A5005987326 @default.
• W2764178891 creator A5009680823 @default.
• W2764178891 creator A5041280886 @default.
• W2764178891 creator A5044363342 @default.
• W2764178891 creator A5045364690 @default.
• W2764178891 creator A5057384424 @default.
• W2764178891 creator A5064276019 @default.
• W2764178891 creator A5068268866 @default.
• W2764178891 creator A5068930601 @default.
• W2764178891 creator A5073503260 @default.
• W2764178891 creator A5078873366 @default.
• W2764178891 creator A5083701333 @default.
• W2764178891 creator A5084003535 @default.
• W2764178891 creator A5090626468 @default.
• W2764178891 date "2017-10-13" @default.
• W2764178891 modified "2023-09-27" @default.
• W2764178891 title "Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study" @default.
• W2764178891 cites W1984705525 @default.
• W2764178891 cites W2003314961 @default.
• W2764178891 cites W2009923660 @default.
• W2764178891 cites W2020640954 @default.
• W2764178891 cites W2020710276 @default.
• W2764178891 cites W2030638161 @default.
• W2764178891 cites W2032144147 @default.
• W2764178891 cites W2036868912 @default.
• W2764178891 cites W2044318901 @default.
• W2764178891 cites W2092773063 @default.
• W2764178891 cites W2094778049 @default.
• W2764178891 cites W2111202604 @default.
• W2764178891 cites W2114843325 @default.
• W2764178891 cites W2126807394 @default.
• W2764178891 cites W2128406046 @default.
• W2764178891 cites W2143747121 @default.
• W2764178891 cites W2153438195 @default.
• W2764178891 cites W2159635467 @default.
• W2764178891 cites W2165107045 @default.
• W2764178891 cites W2166476511 @default.
• W2764178891 cites W2320652365 @default.
• W2764178891 cites W2344059127 @default.
• W2764178891 cites W2525802576 @default.
• W2764178891 doi "https://doi.org/10.1111/apt.14371" @default.
• W2764178891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29027693" @default.
• W2764178891 hasPublicationYear "2017" @default.
• W2764178891 type Work @default.
• W2764178891 sameAs 2764178891 @default.
• W2764178891 citedByCount "22" @default.
• W2764178891 countsByYear W27641788912018 @default.
• W2764178891 countsByYear W27641788912019 @default.
• W2764178891 countsByYear W27641788912020 @default.
• W2764178891 countsByYear W27641788912021 @default.
• W2764178891 crossrefType "journal-article" @default.
• W2764178891 hasAuthorship W2764178891A5003276206 @default.
• W2764178891 hasAuthorship W2764178891A5005106461 @default.
• W2764178891 hasAuthorship W2764178891A5005987326 @default.
• W2764178891 hasAuthorship W2764178891A5009680823 @default.
• W2764178891 hasAuthorship W2764178891A5041280886 @default.
• W2764178891 hasAuthorship W2764178891A5044363342 @default.
• W2764178891 hasAuthorship W2764178891A5045364690 @default.
• W2764178891 hasAuthorship W2764178891A5057384424 @default.
• W2764178891 hasAuthorship W2764178891A5064276019 @default.
• W2764178891 hasAuthorship W2764178891A5068268866 @default.
• W2764178891 hasAuthorship W2764178891A5068930601 @default.
• W2764178891 hasAuthorship W2764178891A5073503260 @default.
• W2764178891 hasAuthorship W2764178891A5078873366 @default.
• W2764178891 hasAuthorship W2764178891A5083701333 @default.
• W2764178891 hasAuthorship W2764178891A5084003535 @default.
• W2764178891 hasAuthorship W2764178891A5090626468 @default.
• W2764178891 hasBestOaLocation W27641788911 @default.
• W2764178891 hasConcept C126322002 @default.
• W2764178891 hasConcept C141071460 @default.
• W2764178891 hasConcept C156957248 @default.
• W2764178891 hasConcept C167135981 @default.
• W2764178891 hasConcept C2777138892 @default.
• W2764178891 hasConcept C2778715236 @default.
• W2764178891 hasConcept C2779134260 @default.
• W2764178891 hasConcept C2779280984 @default.
• W2764178891 hasConcept C2780132546 @default.
• W2764178891 hasConcept C2780479503 @default.
• W2764178891 hasConcept C2781290027 @default.
• W2764178891 hasConcept C44249647 @default.
• W2764178891 hasConcept C71924100 @default.
• W2764178891 hasConceptScore W2764178891C126322002 @default.
• W2764178891 hasConceptScore W2764178891C141071460 @default.
• W2764178891 hasConceptScore W2764178891C156957248 @default.
• W2764178891 hasConceptScore W2764178891C167135981 @default.
• W2764178891 hasConceptScore W2764178891C2777138892 @default.
• W2764178891 hasConceptScore W2764178891C2778715236 @default.
• W2764178891 hasConceptScore W2764178891C2779134260 @default.
• W2764178891 hasConceptScore W2764178891C2779280984 @default.
• W2764178891 hasConceptScore W2764178891C2780132546 @default.
• W2764178891 hasConceptScore W2764178891C2780479503 @default.
• W2764178891 hasConceptScore W2764178891C2781290027 @default.
• W2764178891 hasConceptScore W2764178891C44249647 @default.
• W2764178891 hasConceptScore W2764178891C71924100 @default.

• next